🚀 VC round data is live in beta, check it out!
Astria Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Astria Therapeutics and similar public comparables like MiMedx Group, Guizhou Sanli, Pharmicell, Aarti Pharmalabs and more.
Astria Therapeutics Overview
About Astria Therapeutics
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
Founded
2008
HQ
Employees
78
Website
Sectors
Financials (FY)
EV
$586M
Astria Therapeutics Stock Performance
Astria Therapeutics has current market cap of $714M, and enterprise value of $586M.
Astria Therapeutics' stock price is $12.50.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $586M | $714M | 0.4% | XXX | XXX | XXX | — |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAstria Therapeutics Valuation Multiples
Astria Therapeutics Financial Valuation Multiples
As of March 7, 2026, Astria Therapeutics has market cap of $714M and EV of $586M.
Equity research analysts estimate Astria Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $714M | XXX | $714M | XXX | XXX | XXX |
| EV (current) | $586M | XXX | $586M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Astria Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Astria Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| MiMedx Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Guizhou Sanli | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharmicell | XXX | XXX | XXX | XXX | XXX | XXX |
| Aarti Pharmalabs | XXX | XXX | XXX | XXX | XXX | XXX |
| Zentiva | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Astria Therapeutics M&A Activity
Astria Therapeutics acquired XXX companies to date.
Last acquisition by Astria Therapeutics was on XXXXXXXX, XXXXX. Astria Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Astria Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAstria Therapeutics Investment Activity
Astria Therapeutics invested in XXX companies to date.
Astria Therapeutics made its latest investment on XXXXXXXX, XXXXX. Astria Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Astria Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Astria Therapeutics
| When was Astria Therapeutics founded? | Astria Therapeutics was founded in 2008. |
| Where is Astria Therapeutics headquartered? | Astria Therapeutics is headquartered in United States. |
| How many employees does Astria Therapeutics have? | As of today, Astria Therapeutics has over 78 employees. |
| Is Astria Therapeutics publicly listed? | Yes, Astria Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Astria Therapeutics? | Astria Therapeutics trades under ATXS ticker. |
| When did Astria Therapeutics go public? | Astria Therapeutics went public in 2015. |
| Who are competitors of Astria Therapeutics? | Astria Therapeutics main competitors are MiMedx Group, Guizhou Sanli, Pharmicell, Aarti Pharmalabs. |
| What is the current market cap of Astria Therapeutics? | Astria Therapeutics' current market cap is $714M. |
| Is Astria Therapeutics profitable? | No, Astria Therapeutics is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.